GI Disorders Found Common in Autistic Children

By Betsy Bates

Children with autism spectrum disorders had a 5.3-fold greater probability of having a gastrointestinal disorder than their nonautistic siblings in a large study of families enrolled in the Autism Genetic Resource Exchange Consortium.

Based on these findings, physicians should educate families that gastrointestinal problems appear to be common in children with autism spectrum disorder, many of whom may not be able to communicate their discomfort, according to Dr. Lulu W. Wang, who reported the findings at the annual Western regional meeting of the American Federation for Medical Research held in Carmel, Calif.

Among 651 children with autism spectrum disorders, 43% had a gastrointestinal disorder or chronic gastrointestinal symptoms, compared with just 12% of 165 siblings, said Dr. Wang, a developmental pediatrician who is a fellow at the M.I.N.D. (Medical Investigation of Neurodevelopmental Disorders) Institute of the University of California at Davis and University of California Davis Children's Hospital.

Constipation (20%) and chronic diarrhea (19%) were the most common GI diagnoses represented among children with autism spectrum disorders.

By contrast, gastroesophageal reflux disorder (4.9%) and constipation (3.7%) were the most common diagnoses among their siblings who did not have autism spectrum disorders, she found.

Children who met the full criteria for autistic disorder were quite low functioning and had few language skills. These children had the highest odds ratio for gastrointestinal disorders, 6.4.

Those who nearly met criteria for autism but were higher functioning had the next highest odds of having gastrointestinal problems, 4.5. Children with minimal deficits across the autism spectrum had a lower probability of having gastrointestinal disorders, at an odds ratio of 2.4, compared with siblings who had no autism spectrum disorder.

After controlling for possible confounders, a multivariate analysis showed that autism was significantly associated with GI disorders (OR = 5.3).

Genetic and dietary factors have been postulated as contributors to the high prevalence of gastrointestinal disturbances in children with autism spectrum disorders, but the problem remains largely a mystery, said Dr. Wang in a telephone interview following the meeting.

“We can only speculate, since we only found an association,” she said of the study, coauthored by Dr. Dan Thomas, chief of the division of pediatric gastroenterology and nutrition at Children’s Hospital Los Angeles.

Asked to comment on how diet may play a role in gastrointestinal symptoms, Dr. Wang pointed to a controlled dietary diary study that found association between stool consistency and dietary intake. Children with autism were not consuming greater amounts of carbohydrates than recommended RDA values (Biol. Psychiatry 2007;61:492-7).

Laboratory studies of a randomly selected subset of 35 children with autistic disorder from Dr. Wang’s cohort showed none had celiac markers. The small numbers make that finding statistically inconclusive, but the results agree with mounting evidence that celiac disease is not a likely contributor to the gastrointestinal or autistic symptoms of a majority of children with the disease.

“There are now more genetic studies coming out that may help explain why a subset of children with autism have more gastrointestinal disorders,” she said.

Dr. Wang and Dr. Thomas reported no potential financial conflicts of interest concerning their study.

Among children with autism spectrum disorders, 43% had a GI disorder or chronic GI symptoms.

Dr. Wang

©2008 Cephalon, Inc. All rights reserved. AMRIX 134 May 2009 Printed in USA. AMRIX is produced with Eurocap® Technology.

For more information about AMRIX, call Cephalon Medical Services at 1-800-896-5855 or visit www.AMRIX.com

AMRIX (Cyclobenzaprine Hydrochloride Extended-Release Capsules) is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, and limitation of motion. AMRIX should be used only for short periods (up to 2 or 3 weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. AMRIX has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease or in children with cerebral palsy.

AMRIX is contraindicated in patients who are hypersensitive to any of its components. AMRIX is contraindicated with concomitant use of monoamine oxidase (MAO) inhibitors or within 14 days after their discontinuation. AMRIX may have life-threatening interactions with MAO inhibitors. AMRIX is contraindicated during the acute recovery phase of myocardial infarction, in patients with arrhythmias, heart block conduction disturbances, or congestive heart failure; or in patients with hyperthyroidism. AMRIX may enhance the effects of alcohol, barbiturates, and other CNS depressants. AMRIX should not be used in elderly patients or in patients with impaired hepatic function.

In clinical trials, the most commonly reported adverse reactions (≥3%) with AMRIX were dry mouth, dizziness, fatigue, nausea, dyspepsia, and constipation.

Please see brief summary of full prescribing information on the following page.


Once-daily AMRIX...the proven efficacy of cyclobenzaprine with low rates of somnolence.¹